Cencora (COR)
NYSEHealth CareMedical - DistributionSnapshot 2026-09-04
$330.95-1.86%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - DistributionSnapshot 2026-09-04
Broken: Primary pillar broken — Operating margin near 12.5% next quarter: 1.3% vs 12.5% target.
Cencora is growing steadily with revenue up about 4% to 5% yearly. Profit margins are expected near 12.5% next quarter. The company raised its EPS guidance to about $17.8 for fiscal 2026. It completed a $4.6 billion acquisition to expand healthcare solutions.
Growth could slow below analyst expectations of 7%. Profit margins might compress from the current raised guidance near 12.5%. Management changes and volatile execution could hurt results. Debt from acquisitions may pressure cash flow.
The stock price is about 4% above our fair value near $292, which is 18% below the Street median target. Analysts expect roughly 7% revenue growth, which aligns with company guidance. Our view is more conservative than the Street.
Breaks if: Share repurchases fall significantly short of $1 billion by end 2026
Breaks if: EPS guidance falls below $17.65 for fiscal 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a multi-year view on a company with a strong recent financial performance but fragile earnings quality and volatile management. The current thesis state is intact, supported by recent results and management's execution on priorities.
The market currently prices COR as cheap compared to its peers, with a low expectations gap. However, there is a recognition of the company's fragile execution quality, which could impact future performance.
Management is on track with key priorities, including raising EPS guidance and integrating the OneOncology acquisition. Recent financial results have been strong, but there is a moderate risk of missing future estimates, given the company's history.
The long-term thesis hinges on management's ability to maintain guidance and the performance of the broader healthcare sector. Key factors include the potential impact of economic conditions on job growth and the performance of sector bellwethers.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat and raised EPS guidance support a positive outlook. However, a volume shift from Walgreens may challenge future earnings guidance.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Cencora has raised its adjusted diluted EPS guidance range for fiscal 2026.
Breaks if: Operating margin falls below 11.5% next quarter
Cencora has raised its adjusted diluted EPS guidance range for fiscal 2026.
Breaks if: YoY revenue growth falls below 7% next year
Cencora has raised its adjusted diluted EPS guidance range for fiscal 2026.
Overall, COR's fundamentals appear solid, but external economic factors and management execution will be crucial in the coming years. Not investment advice.